Nektar Therapeutics (NASDAQ: NKTR) kicked off on Monday, up 12.10%% from the previous trading day, before settling in for the closing price of $8.51. Over the past 52 weeks, NKTR has traded in a range of $6.48-$22.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 25.49% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -40.83%. With a float of $11.96 million, this company’s outstanding shares have now reached $12.41 million.
In an organization with 61 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 74.61%, operating margin of -131.01%, and the pretax margin is -147.55%.
Nektar Therapeutics (NKTR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The most recent insider transaction that took place on May 19 ’25, was worth 7,177. In this transaction Chief R&D Officer of this company sold 10,712 shares at a rate of $0.67, taking the stock ownership to the 305,892 shares. Before that another transaction happened on May 19 ’25, when Company’s Chief Legal Officer sold 9,996 for $0.67, making the entire transaction worth $6,697. This insider now owns 314,296 shares in total.
Nektar Therapeutics (NKTR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -40.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.69% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Take a look at Nektar Therapeutics’s (NKTR) current performance indicators. Last quarter, stock had a quick ratio of 3.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.53, a number that is poised to hit -2.98 in the next quarter and is forecasted to reach -12.07 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Let’s dig in a bit further. During the last 5-days, its volume was 0.72 million. That was better than the volume of 0.19 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 24.50%.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 31.69%, which indicates a significant decrease from 34.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 165.08% in the past 14 days, which was higher than the 111.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.04, while its 200-day Moving Average is $14.11. However, in the short run, Nektar Therapeutics’s stock first resistance to watch stands at $10.08. Second resistance stands at $10.61. The third major resistance level sits at $11.48. If the price goes on to break the first support level at $8.68, it is likely to go to the next support level at $7.81. The third support level lies at $7.28 if the price breaches the second support level.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
The company with the Market Capitalisation of 118.36 million has total of 12,413K Shares Outstanding. Its annual sales at the moment are 98,430 K in contrast with the sum of -118,960 K annual income. Company’s last quarter sales were recorded 10,460 K and last quarter income was -50,880 K.
